Edition:
India

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

569.35INR
19 Jan 2018
Change (% chg)

Rs29.75 (+5.51%)
Prev Close
Rs539.60
Open
Rs549.00
Day's High
Rs575.00
Day's Low
Rs545.10
Volume
8,746,829
Avg. Vol
2,807,815
52-wk High
Rs575.00
52-wk Low
Rs295.03

Latest Key Developments (Source: Significant Developments)

Biocon Announces Exclusive Global Collaboration With Sandoz On Next-Generation Biosimilars
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Biocon Ltd ::ANNOUNCES EXCLUSIVE GLOBAL COLLABORATION WITH SANDOZ ON NEXT-GENERATION BIOSIMILARS'.SAYS WORLDWIDE COMMERCIALIZATION REPONSIBILITIES TO BE DIVIDED.  Full Article

Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Biocon Ltd ::CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS.LIBBS FARMACEUTICA TO COMMERCIALIZE PRODUCT IN BRAZIL UNDER BRAND NAME ZEDORA.  Full Article

Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Biocon Ltd ::CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE.SAYS CO'S API UNIT HAS DIFFERENT FEI NO FOR WHICH FACILITY FEE TO U.S. FDA HAD BEEN PAID FOR IN SEPT 2017.  Full Article

EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Mylan NV ::EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM.EMA ACCEPTANCE OF TRASTUZUMAB, PEGFILGRASTIM FOLLOWS EARLIER WITHDRAWAL OF APPLICATIONS IN RESPONSE TO AUDIT OF BIOCON'S DRUG PRODUCT FACILITY.  Full Article

Biocon says co's facility receives EIR with VAI status​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Biocon Ltd :Says ‍Biocon's facility receives EIR with vai status​.  Full Article

Biocon says Mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Biocon Ltd :Says mylan resubmits Biosimilar Trastuzumab and Pegfilgrastim dosseirs with EMA‍​.  Full Article

India's Biocon Sept-qtr consol profit more than halves
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Biocon Ltd :Sept quarter consol profit 688 million rupees versus 1.47 billion rupees last year.Consensus forecast for Sept quarter consol profit was 1.14 billion rupees.Sept quarter consol revenue from operations 9.69 billion rupees versus 9.54 billion rupees last year.Approved transfer of biosimilars business by way of slump sale as a going concern to Biocon Biologics India Ltd, a step down unit of co‍​.Says "expect headwinds to ease by the end of this fiscal"‍​."Malaysia facility costs and pricing pressures in our APIs business continue to weigh on our P&L".  Full Article

Biocon says ‍U.S. FDA issued complete response letter for proposed biosimilar Pegfilgrastim​
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Biocon Ltd ::Says ‍US FDA issues complete response letter (CRL) for proposed biosimilar Pegfilgrastim​.Says ‍CRL did not raise any questions on biosimilarity, pharmacokinetic/pharmacodynamic data, clinical data or immunogenicity​.Says ‍do not expect CRL to impact commercial launch timing of biosimilar Pegfilgrastim in US​.‍CRL relates to pending update of BLA with certain data from facility requalification activities post recent plant modifications​.  Full Article

Biocon Ltd says co and Mylan's proposed biosimilar accepted for review by EMA
Thursday, 21 Jul 2016 

Biocon Ltd : Mylan & Biocon announce regulatory submission for proposed biosimilar Pegfilgrastim accepted for review by European Medicines Agency . Co has exclusive commercialization rights with Mylan for proposed biosimilar in US, Canada, Japan, Australia, New Zealand, European Union countries . Biocon has co-exclusive commercialization rights with Mylan for the product in rest of the world .  Full Article

India's Biocon Ltd June-qtr consol profit up about 35 pct
Thursday, 21 Jul 2016 

Biocon Ltd : India's Biocon Ltd says June-quarter consol net profit 1.67 billion rupees . Says June-quarter consol net sales 9.72 billion rupees . Consensus forecast for June-quarter net profit was 1.18 billion rupees . Says consol net profit in June-quarter last year was 1.24 billion rupees as per Ind-AS; consol net sales was 7.58 billion rupees .  Full Article

BUZZ-India's Biocon hits near 2-week high on tie-up with Sandoz

** Biocon Ltd rises as much as 3.9 pct at 560.35 rupees, its highest since Jan 8

No consensus analysis data available.